Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPular PAUSE TAVI
NCT04437303Phase 4Completed
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial in thromboembolism (2 arms). Primary endpoint: Net adverse clinical events at 30 days. Started Nov 2020; status: completed.
02
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04437303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437303.